| 01 |
Alcohol use(29, 42, 48) |
3 (9.6%) |
| 02 |
Side effects of ART(21, 28, 29, 33, 37, 38, 47, 48, 49) |
9 (29%) |
| 03 |
Illicit drug use(22, 24, 26, 29, 38, 39, 43, 44, 48, 49) |
10 (32.2%) |
| 04 |
Stigma and social isolation(19, 23, 25, 28, 29, 31, 32, 34, 35, 40, 41, 47) |
12 (38.7%) |
| 05 |
Low education level(20, 22, 24, 30, 31, 32, 40, 42, 44, 49) |
10 (32.2%) |
| 06 |
Mental disorders(20, 22, 26, 28, 31, 32, 36, 37, 38, 41, 42, 43, 47) |
14 (45.1%) |
| 07 |
Low i ncome(20, 30, 31, 32, 34, 36, 39, 40, 42, 43, 44, 48) |
12 (38.7%) |
| 08 |
Barriers to accessing healthcare services(19, 22, 23, 25, 26, 27, 32, 36, 38, 40, 42, 43, 44, 45, 46, 49) |
16 (51.6%) |
| 09 |
Lack of support network(19, 21, 22, 25, 31, 32, 35, 37, 38, 40, 41, 42, 44, 48, 49) |
15 (48.3%) |
| 10 |
Forgetfulness(21, 29, 35, 37, 38, 43, 44, 48) |
8 (25.8%) |
| 11 |
Fear of diagnosis disclosure(19, 29, 31, 34, 35, 41, 49) |
7 (22.5%) |
| 12 |
High medication burden(36, 39, 43, 49) |
4 (12.9%) |
| 13 |
Race (Black or Brown)(21, 39, 42) |
3 (9.6%) |
| 14 |
Denial of disease(21, 25, 41) |
3 (9.6%) |
| 15 |
Age < 40 years(20, 28, 36, 39, 42, 46, 48) |
7 (22.5%) |
| 16 |
Occupational activity(24, 29, 30, 31, 40, 41, 46, 49) |
8 (25.8%) |
| 17 |
Quality of care and/or relationship with healthcare professionals(21, 23, 25, 28, 30, 31, 32, 38, 40) |
9 (29%) |
| 18 |
Treatment duration < 1 year(35, 38, 39, 49) |
4 (12.9%) |
| 19 |
Treatment duration < 2 years(19, 37, 40, 48) |
4 (12.9%) |
| 20 |
Self-centeredness(21, 48) |
2 (6.4%) |
| 21 |
Unhealthy environment(29, 41) |
2 (6.4%) |
| 22 |
Absence/deficiency of public policies(24, 27, 30) |
3 (9.6%) |
| 23 |
Malesex(20, 21, 26, 32, 39) |
5 (16.2%) |
| 24 |
Change in therapeutic regimen(33, 39) |
2 (6.4%) |
| 25 |
Medication unavailability(24, 27, 30, 41) |
4 (12.9%) |
| 26 |
Destabilizing situations(19, 25, 29, 31, 37, 42, 45) |
7 (22.5%) |
| 27 |
Food insecurity(19, 27, 34, 40, 45, 46) |
6 (19.3%) |
| 28 |
HIV clinical stage (WHO)(21, 24, 26, 35, 36, 38, 49) |
7 (22.5%) |
| 29 |
Coinfection (hepatitis and tuberculosis)(24, 26, 35, 49) |
4 (12.9%) |
| 30 |
Religion/beliefs opposing the therapeutic plan(21, 35, 44) |
3 (9.6%) |
|
Nº
|
Consequences
|
N(%)
|
| 01 |
Morbimortality(21, 23, 26, 27, 31, 32, 36, 37, 38, 42, 45, 49) |
13 (41.9%) |
| 02 |
Disease progression(21, 23, 26, 27, 31, 32, 36, 37, 38, 42, 45, 49) |
15 (48.3%) |
| 03 |
Increased susceptibility to opportunistic infections(28, 30, 34, 35, 36, 38, 40, 46, 48) |
9 (29%) |
| 04 |
Increased transmissibility potential(22, 30, 37, 39, 43, 45, 49) |
7 (22.5%) |
| 05 |
Medication resistance(21, 22, 23, 26, 28, 29, 31, 32, 33, 34, 36, 38, 39, 42, 44, 46, 49) |
17 (54.8%) |
| 06 |
Increased viral load(21, 22, 23, 26, 28, 29, 31, 32, 33, 34, 35, 36, 37, 39, 43, 44, 45) |
17 (54.8 %) |
| 07 |
Reduced quality of life(28, 31, 34, 36, 39, 46) |
6 (19.3%) |
| 08 |
Neurological and/or motor dysfunctions(6, 20, 22, 31, 42, 48) |
4 (12.9%) |
| 09 |
Recurrent and/or prolonged hospitalizations(27, 44) |
2 (6.4%) |